Latest Healthcare Innovation News

Anteris Technologies has updated the timetable for its Australian capital raising, delaying settlement to November 4 and the start of trading for new securities to November 5. The company also highlights restrictions on U.S. investors acquiring its CDIs.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

Resmed Inc. kicked off fiscal 2026 with robust 9% revenue growth and a notable 290 basis points gross margin expansion, signaling strong momentum in home healthcare innovation. The company also declared a $0.60 dividend and executed a $150 million share buyback, underscoring confidence in its strategic direction.

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.

Biotron Limited has advanced its Hepatitis B antiviral program while preparing to acquire Sedarex Limited, backed by a $2.5 million capital raise. The move signals a strategic expansion into safer anaesthetics alongside ongoing R&D progress.

4DMedical Limited has secured FDA clearance and immediate Medicare reimbursement for its groundbreaking CT – VQ™ lung imaging technology, accelerating commercial adoption across the US, Brazil, and Australia.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Austco Healthcare kicks off FY26 with a robust 51% revenue increase and improved profitability, driven by strong organic growth and strategic acquisitions.

Talius Group has raised $4 million in a recent placement, expanding its subscription base and preparing to capitalize on new aged care legislation set to take effect in November 2025.

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

ReNerve Limited reported a 38% increase in quarterly sales driven by the launch of its EmpliQ product range and ongoing development of advanced nerve repair technologies. The company’s cash position remains solid as it prepares for upcoming clinical trials.